Seroatlas · Human Serome Atlas

SPRED2

Sprouty-related, EVH1 domain-containing protein 2

Also known as: FLJ21897, FLJ31917, SPRE2_HUMAN, Spred-2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q7Z698
Gene: SPRED2
Ensembl: ENSG00000198369
Chromosome: 2
Canonical length: 418 aa
Protein class: Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Nucleoplasm,Cytosol
Quaternary structure: Homodimer

OverviewNCBI Gene

SPRED2 is a member of the Sprouty (see SPRY1; MIM 602465)/SPRED family of proteins that regulate growth factor-induced activation of the MAP kinase cascade (see MAPK1; MIM 176948) (Nonami et al., 2004 [PubMed 15465815]).[supplied by OMIM, Mar 2008]

Canonical amino-acid sequenceUniProt

418 residues, UniProt reviewed canonical sequence.

>Q7Z698|SPRED2
     1  MTEETHPDDD SYIVRVKAVV MTRDDSSGGW FPQEGGGISR VGVCKVMHPE GNGRSGFLIH
    61  GERQKDKLVV LECYVRKDLV YTKANPTFHH WKVDNRKFGL TFQSPADARA FDRGVRKAIE
   121  DLIEGSTTSS STIHNEAELG DDDVFTTATD SSSNSSQKRE QPTRTISSPT SCEHRRIYTL
   181  GHLHDSYPTD HYHLDQPMPR PYRQVSFPDD DEEIVRINPR EKIWMTGYED YRHAPVRGKY
   241  PDPSEDADSS YVRFAKGEVP KHDYNYPYVD SSDFGLGEDP KGRGGSVIKT QPSRGKSRRR
   301  KEDGERSRCV YCRDMFNHEE NRRGHCQDAP DSVRTCIRRV SCMWCADSML YHCMSDPEGD
   361  YTDPCSCDTS DEKFCLRWMA LIALSFLAPC MCCYLPLRAC YHCGVMCRCC GGKHKAAA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SPRED2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.48
Highest tissue expression: 27 nTPM

Expression across tissuesHPA

Tissue

thymus: 27 nTPM
liver: 23 nTPM
cerebral cortex: 22 nTPM
adipose tissue: 21 nTPM
breast: 20 nTPM
stomach: 19 nTPM

Single-cell type

urothelial cells: 364 nCPM
bergmann glia: 288 nCPM
fibro-adipogenic progenitors: 271 nCPM
renal collecting duct intercalated cells: 268 nCPM
respiratory basal cells: 256 nCPM
salivary acinar cells: 231 nCPM

Immune cell

plasmacytoid DC: 4.3 nTPM
NK-cell: 1.9 nTPM
intermediate monocyte: 0.7 nTPM
total PBMC: 0.7 nTPM
gdT-cell: 0.6 nTPM
neutrophil: 0.6 nTPM

Brain region

cerebral cortex: 58 nTPM
medulla oblongata: 42 nTPM
basal ganglia: 40 nTPM
thalamus: 40 nTPM
hippocampal formation: 38 nTPM
midbrain: 38 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SPRED2.

Disease | AllUniProt

Conditions SPRED2 is implicated in, by any mechanism.

Noonan syndrome 14 (NS14) MIM:619745

Disease | GeneticClinVar

5 pathogenic / likely-pathogenic of 102 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Noonan syndrome 14
Noonan syndrome

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.07
gnomAD pLI: 0
gnomAD missense Z: 1.31
DepMap mean gene effect: 0.18
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SPRED2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SPRED2 as an antibody target. Whether an autoantibody or antibody against SPRED2 could matter depends on whether native SPRED2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SPRED2 is annotated at the cell surface, where native SPRED2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SPRED2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...